How A Simple Name Change from PCOS to PMOS Can Impove Women's Health

Why Medical Language Matters: How the Label PMOS Will Improve Women's Health

In May of 2026, a groundbreaking paper having the potential to change the lives of millions of women was published. This paper is unique in that it did not unveil a new medication or present evidence of a novel biological phenomenon; instead, it revealed a new name for an existing health condition. The Lancet, an international medical journal, has announced that polycystic ovary syndrome (PCOS) will be renamed polyendocrine metabolic ovarian syndrome (PMOS) (Teede et al., 2026). This updated label more accurately reflects the biology and diagnostic criteria of the condition, which has tremendous implications for improving diagnostic time, enhancing quality of care, reducing stigma, and supporting policy and research efforts (Teede et al., 2026).

Art By Shea Davis

The Impact of Language on Health

PMOS affects approximately 170 million women of reproductive age, and yet a startling 70% of those women remain undiagnosed (Teede et al., 2026). A variety of factors contribute to this injustice, but the misleading name "polycystic ovary syndrome" has certainly played a significant role. The label incorrectly implies that ovarian cysts are the defining feature of the condition, while ignoring the hormonal and metabolic aspects. The result was confusion among patients and healthcare professionals alike, leading to severe health consequences for those affected by the condition. For years, we have consistently witnessed delayed diagnosis, fragmented care, patient dissatisfaction, large knowledge gaps, insufficient research, stunted advocacy efforts, and constraints to healthcare policy (Teede et al., 2026).

The new name "polyendocrine metabolic ovarian syndrome" critically highlights the hormonal and metabolic pathways underlying many features of this condition. The term “polyendocrine” refers to changes in hormone levels, particularly androgens, that define the syndrome. “Metabolic” addresses changes in insulin resistance and the compensatory increases in insulin levels observed in most patients, which can lead to secondary metabolic issues. And “ovarian” refers to the disrupted ovulation and menstruation we typically think of with PMOS, which can result in cyst formation (Teede et al., 2026). 

PMOS is a chronic condition that impacts many aspects of a woman’s health; it is not merely a reproductive problem, and it's time we stop treating it as such. Patients should be aware of the multitude of symptoms they may encounter, have access to high-quality care, and receive research and policies that support their needs. This name change is the first step in such a transformation. The research implications of this change are particularly promising because funding outside of the fairly small reproductive health budget may become available (Astor, 2026). Notably, research could lead to better treatment options for the condition. Currently, patients are prescribed medication approved to treat only a symptom of PMOS, like infertility or obesity, rather than the condition itself (Dong & Rees, 2023). However, as our understanding of the underlying biology of PMOS improves and funding increases, the prospect of developing treatments targeting the root causes of the condition becomes more likely. Enhancing care in these areas has tremendous potential to significantly improve the quality of life for the millions of women living with PMOS.

Matching Biology to Language

The defining characteristic of PMOS is a widespread hormonal imbalance that primarily affects the metabolic and reproductive systems (Cleveland Clinic, 2023). Several hormones are out of balance in individuals with PMOS, all of which seem to originate from a region of the brain called the hypothalamus. Here, gonadotropin-releasing hormones (GnRH) are released in a rhythmic pattern, triggering the pituitary gland to release the reproductive hormones luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In individuals with PMOS, these GnRH pulses occur more frequently, leading to increased LH levels and decreased FSH levels. 

It is these two hormonal changes that are directly responsible for the hallmark symptoms of PMOS. The increase in LH causes the ovaries to produce an excess of androgens, which contributes to many of the symptoms seen with PMOS. Androgens are hormones typically found in higher levels in men, but their elevation in women can cause several health issues (Alemany, 2022; Dong & Rees, 2023). Meanwhile, the decrease in FSH causes small ovarian sacs containing immature eggs to prematurely stop their development (Dong, J., & Rees, 2023). When these eggs do not mature, they are often not released, leading to irregular or absent ovulation and menstruation (Cleveland Clinic, 2023). This situation can result in multiple follicles remaining in the ovaries, which may develop into cysts (Cleveland Clinic, 2023). These reproductive hormonal imbalances are also apparent in many other features of the condition, including infertility, pregnancy complications, abnormal hair growth, and risk of endometrial cancer (Teede et al., 2026).

PMOS also significantly affects metabolism because androgens decrease the body’s sensitivity to insulin. To compensate for this decreased sensitivity, the pancreas produces more insulin to help absorb sugar from the bloodstream for energy (Cleveland Clinic, 2023; Dong & Rees, 2023). While this hyperinsulinism allows the body to function, it comes with serious consequences such as obesity, type 2 diabetes, hypertension, cardiovascular disease, sleep apnea, and more (Teede et al., 2026). Interestingly, the relationship works in the other direction as well, with high insulin levels stimulating production of more androgens, creating a vicious cycle of hormonal imbalance (Dong & Rees, 2023). 

While the primary dysfunction lies in ovarian and metabolic endocrine systems for individuals with PMOS, there may be other systems impacted. Dermatological features are common and can include acne, alopecia, male-pattern hair growth, skin tags, and dark patches of skin (Cleveland Clinic, 2023; Teede et al., 2026). More recently, there has also been evidence of neurological hormonal imbalances that may contribute to mental health conditions such as depression, anxiety, eating disorders, and poor quality of life (Teede et al., 2026).

Choosing a New Name

There has been ongoing discussion about changing the name “polycystic ovary syndrome” since 2012, but initiatives have continuously stalled until now. To ensure progress, the Global Name Change Consortium assembled a team of experts to conduct thorough research on what changes should be made and how to implement them. This group gathered 56 organizations to collaborate on the project, incorporating feedback from academics, doctors, and patients. Initial surveys found 84% of respondents endorsed implementation of a new name, paving the way for researchers to move forward with the project. 

Choosing the new name was a two-step process. First, a variety of similar terms that described the endocrine, metabolic, and reproductive features of the condition were surveyed to assess which were preferred. In the second step, several names and acronyms generated from the most popular terms were voted on. Ultimately, "polyendocrine metabolic ovarian syndrome" (PMOS) held the majority of votes at 66% of those surveyed (Teede et al., 2026).  

Throughout this entire process, the committee prioritized several key principles: support for clinical outcomes, scientific accuracy, clarity, avoidance of stigma, cultural appropriateness, and feasibility of implementation. These foci are clearly reflected in the changes made, as the new name enhances accuracy while keeping the acronym similar enough to avoid confusion. Furthermore, publishing this paper is only the beginning of a global implementation strategy; the authors clearly outlined a comprehensive transition period focused on education, engagement, and integration into healthcare systems to ensure the change achieves all its intended positive impacts (Teede et al., 2026).

Conclusion

Although the name change may appear simple, its impacts are vast. From diagnosis to treatment and from advocacy to policy, this change will ultimately improve the lives of everyone impacted by PMOS at every level. I also believe this project has broader implications, as it used women's health as its guiding purpose. This focus has been crucial to its success thus far, and we hope to see more of this intentionality and compassion for women's health in the future.

References

Alemany, M. (2022, October 8). The roles of androgens in humans: Biology, metabolic regulation and health. International journal of molecular sciences. https://pmc.ncbi.nlm.nih.gov/articles/PMC9569951/

Astor, M. (2026a, May 12). P.C.O.S. has a new name. Doctors hope it will improve care for millions. New York Times. https://www.nytimes.com/2026/05/12/well/live/pcos-pmos- name-change-treatment-health.html 

Cleveland Clinic. (2023, February 15). PMOS (polyendocrine metabolic ovarian syndrome): Symptoms & treatment. https://my.clevelandclinic.org/health/diseases/8316-polycystic-ovary-syndrome-pcos

Dong, J., & Rees, D. A. (2023, October 12). Polycystic ovary syndrome: Pathophysiology and therapeutic opportunities. BMJ medicine. https://pmc.ncbi.nlm.nih.gov/articles/PMC10583117/ 

Teede, H. J., Bahri Khomami, M., Morman, R. M., Laven, J. S. E., Joham, A. E., Costello, M. F., Patil, M., Rees, A., Berry, L., Cree, M. G., Zhao, H., Norman, R. J., Dokras, A., & Piltonen, T. (2026, May 12). Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: A multistep global consensus process. The Lancet. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00717-8/fulltext